Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 29 March 2024, 14:19 HKT/SGT
Share:
    

Source: Eisai
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that “NouKNOW®”, Eisai’s self-check tool for brain health, was certified as a “ME-BYO BRAND” by Kanagawa prefecture.

About ”ME-BYO BRAND”

“ME-BYO BRAND”, is a certification granted to excellent products/services associated with pre-symptomatic diseases by Kanagawa Prefectural Government in an effort to raise awareness toward pre-symptomatic diseases and promote commercialization of endorsed products/services. It recognizes products/services that contribute to the visualization of pre-symptomatic diseases in the areas of lifestyle, life functions, mental health/stress, and cognitive function, which lead to changes in the awareness and behavior of Kanagawa prefecture residents.

“NouKNOW”, a Self-Check Tool for Brain Health

NouKNOW (non-medical device) is a tool that uses a simple card test using a PC, tablet or smartphone device to perform tests evaluating psychomotor function, attention, learning and memory, and working memory. The results screen displays quantified indicators of brain performance, such as “memorization”, “cognition”, and “decision”, along with lifestyle advice. This digital tool allows users to self-assess independently and in a short time frame (approx. 15 minutes), enabling regular assessments in instances such as daily life and health checkups. It has been adopted by a number of medical and research institutions, municipalities, corporations and universities. It is expected that use of this tool to perform regular self-checks of brain health will become an opportunity to help the generation currently in their prime working years to gain a correct understanding of brain health and diseases, as well as to reconsider daily lifestyle, greater preventive measures, and consultation with doctors and other healthcare professionals.

For additional information, please visit https://nouknow.jp/. (Japanese only)
(List of partners: https://nouknow.jp/partner/

*The purpose of this tool is not to prevent or diagnose disease, but to raise awareness of brain health through regular checks.

Eisai will collaborate with local governments across Japan to create a community where citizens are aware of and check their brain health from the stage where they are healthy, aiming to realize a “Dementia-Inclusive Society” where everyone can live their lives how they would like.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Nov 28, 2024 15:26 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: